RxDoctor Payments Data

Jeffrey Humbarger, MD

Internal Medicine · Sarasota, FLNPI 1447249172

Payments from drug & device makers

$1,546in general payments, 2019–2025

Across 56 payments — averaging $27.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$611
  • Novo Nordisk$232
  • Pfizer$166
  • Intuitive Surgical$135
  • Amgen$100
  • Bayer$96
  • plus $205 from 6 others

What the payments were for

  • Food & beverage$1,546100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,546 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$239,077
Medicare patients
708
Services billed
2,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$184,422
OzempicSemaglutide32$32,277
XareltoRivaroxaban17$19,541
MyrbetriqMirabegron11$15,933
Breo ElliptaFluticasone/Vilanterol22$11,488
FarxigaDapagliflozin Propanediol13$9,773
Advair HfaFluticasone Propion/Salmeterol17$8,622
Atorvastatin Calcium729$6,791
SymbicortBudesonide/Formoterol Fumarate14$6,687
Levothyroxine Sodium398$4,260
Losartan Potassium388$3,704
Rosuvastatin Calcium271$3,686
SynthroidLevothyroxine Sodium49$3,440
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen63$3,139
Pantoprazole Sodium254$3,022

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$166$184,422189 claims
Novo NordiskOzempic$232$32,27732 claims
AstraZenecaFarxiga, Symbicort$28$16,45927 claims
AbbVieSynthroid$19$3,44049 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →